Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291824 | 0.83 | DRD2 (0.52) | DRD2DRD4ACHESIGMAR1BCHE | |
| SCHEMBL9382368 | 0.81 | DRD2 (0.54) | DRD2DRD4ACHEBCHEMAOA | |
| SCHEMBL9381185 | 0.79 | ACHE (0.52) | DRD2DRD4ACHEBCHEMAOA | |
| SCHEMBL4737625 | 0.79 | DRD2 (0.61) | DRD2DRD4ACHESIGMAR1BCHE | |
| SCHEMBL252049 | 0.78 | NAMPT (0.56) | DRD2DRD4NAMPTACHESIGMAR1 | |
| SCHEMBL5267754 | 0.77 | DRD2 (0.51) | DRD2DRD4ACHESIGMAR1BCHE | |
| SCHEMBL7501904 | 0.76 | DRD2 (0.63) | DRD2DRD4ACHESIGMAR1BCHE | |
| SCHEMBL4590232 | 0.73 | DRD2 (0.52) | DRD2DRD4ACHESIGMAR1BCHE | |
| SCHEMBL4696031 | 0.72 | BCHE (0.55) | DRD2DRD4ACHEBCHE | |
| SCHEMBL9381126 | 0.72 | DRD2 (0.52) | DRD2DRD4ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009158646-A1 | THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |